TidalSense is an AI-powered respiratory diagnostics company headquartered in Cambridge, UK, dedicated to transforming the detection and management of respiratory conditions through advanced sensor technology, artificial intelligence, and digital health innovation. Led by CEO Dr. Ameera Patel, the company develops solutions designed to make respiratory diagnosis faster, more accessible, and more efficient for healthcare providers and patients.

Respiratory diseases remain one of the most pressing challenges in healthcare, with millions of patients experiencing delayed diagnosis due to limitations in traditional testing methods. Chronic obstructive pulmonary disease (COPD), one of the leading causes of respiratory-related mortality, often remains undetected until symptoms become more severe. Conventional diagnostic approaches such as spirometry require specialized equipment, trained professionals, and patient cooperation with forceful breathing techniques, creating accessibility and capacity challenges across healthcare systems.

Redefining Respiratory Diagnostics Through AI and Sensor Innovation

TidalSense’s flagship solution, N-Tidal® Diagnose, is designed to identify COPD through AI-powered analysis of tidal breathing patterns rather than traditional spirometry. The technology works alongside N-Tidal hardware to capture carbon dioxide (CO₂) waveforms, known as capnograms, during normal breathing. These signals are analyzed by proprietary AI models trained on more than 2.5 million patient breaths, enabling rapid assessment at the point of care.

Unlike conventional spirometry, N-Tidal® Diagnose does not require forceful exhalation, specialist qualifications, or hospital-grade equipment. The solution allows healthcare professionals to perform assessments more efficiently while expanding access to respiratory diagnostics across primary care, community healthcare, and other clinical settings.

TidalSense’s innovation is built on its patented sensor technology, which provides high-accuracy and rapid sampling of CO₂ to generate deeper insights into lung physiology. Combined with the company’s cloud platform and artificial intelligence capabilities, this technology foundation supports the development of next-generation respiratory diagnostic and monitoring solutions.

In March 2025, N-Tidal® Diagnose became the first non-spirometry AI diagnostic device to receive a CE mark under EU MDR (Class IIa) for COPD. The solution has since been commissioned and deployed across multiple healthcare settings, including NHS deployments in the UK, supporting wider adoption of AI-enabled respiratory diagnostics.

Scaling Global Access to Next-Generation Respiratory Care

TidalSense’s growing impact has attracted significant investor support. The company has raised $40 million to date, including $11 million in grants from organizations such as Innovate UK, SBRI, NIHR, and Asthma + Lung UK. The funding supports commercialization efforts across the UK and Europe while advancing expansion into international markets, including the United States.

With its combination of artificial intelligence, sensor technology, and clinical expertise, TidalSense is helping redefine respiratory diagnostics by making accurate detection faster, more accessible, and scalable. As healthcare systems increasingly prioritize early intervention and data-driven care, the company represents a new generation of MedTech innovators advancing the future of respiratory health.

N-Tidal Diagnose: Point of Care COPD Diagnostic Test

N-Tidal® Diagnose is a CE-marked point-of-care diagnostic solution for COPD that combines precise measurement of respiratory physiology through the N-Tidal® medical device with automated data interpretation powered by TidalSense’s diagnostic AI algorithms. The solution analyzes respiratory signals from the breath test and delivers an accurate COPD diagnosis with severity staging in as little as five minutes.

A Unique COPD Diagnostic Solution

N-Tidal® Diagnose is a regulated, secure Class IIa medical device diagnostic solution delivered as a service. The technology combines advanced N-Tidal® hardware with AI-powered diagnostic software to deliver COPD diagnosis at the point of care within minutes.

Powered by patented sensor technology, N-Tidal® Diagnose performs real-time geometric analysis of CO₂ breath waveforms to provide highly sensitive quantification of lung function from relaxed breathing. The solution captures detailed respiratory data through a simple, connected handset designed for ease of use across clinical settings.

Simple, Connected Handset: N-Tidal® features a patented, industry-leading sensor that captures high-resolution respiratory CO₂ data from just 75 seconds of relaxed breathing. The compact design enables healthcare professionals to collect detailed physiological information without the complexity associated with traditional diagnostic methods.

Automated Data Transfer and Interpretation: The captured data is automatically transferred through 4G connectivity in near real time, processed into N-Tidal digital biomarkers, and analyzed through N-Tidal® Diagnose AI algorithms. This automated workflow reduces manual interpretation requirements and supports efficient clinical decision-making.

Rapid, Transparent Diagnostic Output: N-Tidal® Diagnose AI algorithms automatically interpret respiratory data and generate a diagnostic test report through the dashboard as a downloadable PDF. By providing clear results without requiring specialist interpretation, the solution supports faster COPD assessment and broader access to respiratory diagnostics.

Fast, Easy, Accurate

COPD remains significantly underdiagnosed, with late diagnosis continuing to be a widespread challenge. Existing diagnostic approaches alone are not sufficient to address the growing need for faster and more accessible respiratory assessment. N-Tidal® Diagnose is designed to transform COPD diagnosis by simplifying testing while delivering rapid and reliable results.

Easy to Use: N-Tidal® Diagnose is designed for straightforward operation. Healthcare professionals can switch on the device, provide it to the patient, and perform testing using a cordless, portable, and connected solution.

Easy for Patients: The solution requires only 75 seconds of relaxed tidal mouth breathing, providing a simpler and more comfortable alternative to traditional diagnostic methods.

Accurate Diagnosis: N-Tidal® Diagnose provides rapid diagnostic results through an online dashboard and downloadable PDF report. The solution delivers high diagnostic performance, with test sensitivity of 90% and specificity of 88%.

Remote Patient Monitoring with N-Tidal Digital Biomarkers

N-Tidal® offers a powerful CE-marked remote patient monitoring solution that enables sensitive quantification of lung physiology in obstructive airway conditions. Powered by first-in-class sensor technology, the solution captures valuable respiratory data through digital biomarkers, supporting continuous monitoring and more informed clinical decision-making.

Sensitive Detection of Airway Obstruction

Leveraging patented sensor technology, N-Tidal® Capture performs real-time geometric analysis of CO₂ breath waveforms to provide highly sensitive quantification of lung function from relaxed breathing within minutes. The solution captures respiratory data through the N-Tidal® Handset, which incorporates advanced CO₂ sensing technology designed to measure airway physiology without requiring forceful breathing maneuvers.

The captured data is automatically transferred through 4G connectivity and processed through TidalSense’s cloud platform, where it is transformed into real-time digital biomarkers. These insights are analyzed through the TidalSense AI engine to support advanced respiratory monitoring and diagnostic capabilities.

The platform supports two key solutions: N-Tidal® Diagnose, which provides an AI-powered diagnostic dashboard for COPD assessment, and N-Tidal® Capture, which enables remote monitoring through a dedicated monitoring dashboard.

N-Tidal® Capture

N-Tidal® Capture is a CE-marked remote patient monitoring solution designed for obstructive airway conditions, including asthma and COPD. The technology provides clinicians with real-time access to N-Tidal® obstructive airway biomarkers through a dedicated clinical dashboard, supporting continuous monitoring of respiratory health.

Registered with the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Italian Ministry of Health, N-Tidal® Capture enables patients to use the N-Tidal® device up to twice daily before routine inhaler use or as prescribed. The collected data is automatically uploaded through mobile networks and processed into N-Tidal® biomarkers in real time.

Through the N-Tidal® Capture dashboard, clinicians can visualize longitudinal patient physiology data, gaining deeper insights into respiratory trends and supporting more informed care decisions.

DR. AMEERA PATEL, MD PH.D. | CEO

Ameera Patel is a serial entrepreneur, applied scientist, and medical doctor with a Ph.D. in applied mathematics and computational neuroscience from the University of Cambridge. After working in the NHS, she joined Microsoft Research's Healthcare AI team. She has invented internationally adopted signal engineering methods, now used in more than 240 leading institutions worldwide, and has led the successful commercialization of healthcare infrastructure software. Ameera regularly advises on healthcare policy, clinical transformation, medical devices, and AI technologies. She has held multiple technology leadership roles and is passionate about building cross-functional, diverse teams to translate innovation into real-world impact. Ameera is responsible for commercial, clinical, and product strategy while maintaining technical leadership in software and AI.